On September 8, 2020 Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, reported that its President & Chief Executive Officer, Christopher U. Missling, PhD, will present a company update at both the Cantor Fitzgerald Global Healthcare Conference 2020 and the H.C. Wainwright 22nd Annual Global Investment Conference (Press release, Anavex Life Sciences, SEP 8, 2020, http://www.anavex.com/anavex-life-sciences-to-present-at-upcoming-global-healthcare-conferences-cantor-fitzgerald-global-healthcare-conference-2020-and-h-c-wainwright-22nd-annual-global-investment-conference/ [SID1234564713]). The conferences are both virtual and details of the presentations are below.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Cantor Global Healthcare Conference 2020
When: Thursday, September 17th, 2020 at 12:40 pm ET.
A live webcast is available at: View Source
C. Wainwright 22nd Annual Global Investment Conference
When: Monday, September 14th, 2020 at 12:00 pm ET.
A live webcast is available to clients of the firm at View Source